Blue Owl Capital Holdings’s Palvella Therapeutics PVLA Stock Holding History

Blue Owl Capital Holdings’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.9M	Sell	31,259 -9,000	-22%	-$939K	1.05%	25
2025 Q4	$4.21M	Sell	40,259 -55,000	-58%	-$4.69M	1.3%	23
2025 Q3	$5.97M	Sell	95,259 -30,000	-24%	-$1.34M	1.85%	19
2025 Q2	$2.82M	Sell	125,259 -15,000	-11%	-$352K	0.91%	26
2025 Q1	$3.93M	Sell	140,259 -109,803	-44%	-$2.12M	1.27%	22
2024 Q4	$3M	Buy	+250,062	New	+$3.93M	0.69%	28

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Blue Owl Capital Holdings's PVLA Position: Q1 2026 in Review

Blue Owl Capital Holdings reduced its Palvella Therapeutics (PVLA) stake by 22% in Q1 2026, selling an estimated $939K and leaving 31,259 shares worth $3.9M. The position accounts for 1.05% of the portfolio, ranked #25.

Blue Owl Capital Holdings first reported a position in PVLA in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.97M in Q3 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Blue Owl Capital Holdings held 31,259 shares of Palvella Therapeutics worth $3.9M as of Q1 2026.
Blue Owl Capital Holdings sold 9,000 Palvella Therapeutics shares in Q1 2026, an estimated $939K.
Palvella Therapeutics made up 1.05% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #25 holding.
Blue Owl Capital Holdings first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 6 quarters since.
Blue Owl Capital Holdings's Palvella Therapeutics position peaked at $5.97M in Q3 2025.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.